The human uterus possesses a remarkable capacity for immune system regeneration even after transplantation, a new study reveals. Researchers have discovered that the uterine immune environment can be successfully rebuilt, even in the presence of immunosuppressant drugs like tacrolimus, traditionally used to prevent organ rejection. This finding challenges existing understanding of uterine immunology and opens new avenues for improving treatment for infertility, post-transplantation recovery, and uterine-related diseases.
This unexpected resilience stems from the uterus’s unique ability to reconstitute its immune cell populations, even receiving contributions from male donor stem cells in the case of uterine transplantation. The research, published on March 11, 2026, in Science Translational Medicine, utilized advanced techniques like single-cell RNA sequencing and flow cytometry to map the origins and characteristics of these cells, offering unprecedented insight into the complex interplay of immunity within the uterus. Understanding this process could lead to better therapies for conditions impacting reproductive health.
Immune Reconstitution Despite Immunosuppression
Traditionally, tacrolimus is administered after organ transplantation, including uterus transplants, to suppress the immune system and prevent the recipient’s body from rejecting the new organ. However, the study found that despite tacrolimus treatment, the uterine immune system was able to rebuild itself. “An unexpected finding was that stem cells from male donors could as well establish a functioning immune environment in the uterus. We observed that the immune system was rebuilt despite the drug tacrolimus, which normally suppresses the immune system,” explained Professor Niklas Björkström, at the Department of Medicine, Huddinge.
The research team studied women following uterus transplantation and those who had regained ovarian function after bone marrow transplantation. They employed sophisticated methods to analyze the cells, including single-cell RNA sequencing to understand gene expression patterns and flow cytometry to identify different cell types. Advanced image analysis was then used to determine the precise positioning of these cells within the uterine tissue. This comprehensive approach allowed researchers to trace the origins and characteristics of the immune cells, revealing the dynamic nature of the uterine immune environment.
Redefining Understanding of Uterine Immune Cells
The results of the study are reshaping the understanding of how specialized immune cells within the uterus develop and are maintained. The research suggests a more complex and adaptable system than previously thought. This knowledge is considered central to understanding a range of reproductive health issues, including fertility challenges, pregnancy complications, and the recovery process following transplantation.
“This knowledge is central to understanding fertility, pregnancy complications, and recovery after transplantation. It gives us the opportunity to develop better treatments for involuntary childlessness, post-transplantation, and for diseases where the uterine immune system plays a role,” Björkström stated.
Future Research Directions
The next phase of research will focus on identifying the signals that guide immune cells to their correct locations within the uterus and ensure they become integrated into the tissue. Researchers also plan to investigate how this process is influenced by the menstrual cycle and pregnancy, as well as how it may be affected by infertility and pregnancy complications.
The study was a collaborative effort involving researchers at the Sahlgrenska Academy, University of Gothenburg, led by Mats Brännström. Funding for the research was provided by the EU through the European Research Council (ERC), the Swedish Research Council, the Swedish Foundation for Strategic Research (SSF), the Swedish Society for Medical Research (SSMF), the Swedish Cancer Society, the Novo Nordisk Foundation, and CIMED.
The findings regarding tacrolimus exposure and its impact on overall survival after allogeneic stem cell transplantation are also being investigated separately. A study published in Frontiers in Pharmacology in April 2025 found that tacrolimus exposure during the first three months after transplantation can predict overall survival rates, suggesting the potential for individualized dosing strategies ([Frontiers in Pharmacology, 2025](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1517083/full)). This highlights the complex relationship between immunosuppression and immune reconstitution in transplant recipients.
As research continues, a deeper understanding of the uterine immune system promises to unlock new therapeutic strategies for a wide range of reproductive health challenges. The ability to manipulate and enhance this natural regenerative capacity could significantly improve outcomes for individuals facing infertility, undergoing transplantation, or battling uterine-related diseases.
This is a developing area of research, and further studies are needed to fully elucidate the mechanisms involved. We encourage readers to share their thoughts and experiences in the comments below.
Disclaimer: This article provides informational content and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
